Markets
markets
Tom Jones

Deckers sinks on cautious full-year outlook that falls below estimates, compounding a miserable year for the Ugg maker

Deckers, the shoe maker behind brands like Ugg and Hoka running sneakers, has dropped about 11% in premarket trading after issuing a cautious outlook for its current fiscal year last night.

While revenue and profit both rose in the second quarter, up 9.1% and 9.7%, respectively, investors focused on the company’s forecast for the full fiscal year, where it expects sales to come in at $5.35 billion, some way short of the $5.46 billion analysts had estimated, per FactSet figures cited by The Wall Street Journal.

The language around the full-year guidance, which is already weaker than anticipated, has also got Deckers investors worried, with the company stating:

This outlook assumes no meaningful changes to the Company’s business prospects or risks and uncertainties identified by management that could impact future results, which include but are not limited to: changes in macroeconomic conditions, including consumer confidence, discretionary spending, inflationary pressures, and foreign currency fluctuations; changes to global trade policy, including tariffs and trade restrictions; geopolitical tensions; and supply chain disruption.

The shoe company’s shares are down more than 55% in 2025 at the time of writing.

More Markets

See all Markets
(J. Edward Moreno/Sherwood News)

Novo and Lilly agree prices are falling — and disagree on what comes next

Novo Nordisk and Eli Lilly are cutting prices to reach more patients — with sharply different expectations about what that means for sales.

markets

Ozempic is no longer the most-searched for GLP-1 in the US

Ozempic, the popular diabetes drug made by Novo Nordisk, used to be short hand for an entire class of diabetes and weight-loss medications. Not anymore.

According to Google Trends data, as of January more people in the US are searching for Eli Lilly’s weight loss shot, Zepbound, than Ozempic. At the same time, interest in the word “Ozempic” now sits roughly on par with searches for “peptides," a catch-all term for a booming, loosely regulated category of experimental supplements.

The numbers hint at a cultural shift: Ozempic is no longer the only word people reach for when they think about weight-loss drugs. The market — and the vocabulary around it — is fragmenting.

This shift also reflected in sales numbers. For several quarters now, Lilly's diabetes and weight loss drugs have outsold Novo's and that gap is expected to widen this year.

markets

Crypto crumble smokes bitcoin-sensitive stocks and speculative tech

It’s a rough day out there, with the pain in the crypto markets being felt among select subgroups of US equities. Shortly before 2 p.m. ET on Wednesday here’s a snapshot of where some of the worst pinches are.

There is some overlap between some of these baskets, for instance bitcoin treasury company Strategy figures both in the “bitcoin sensitive” and “meme” basket. But in general it’s just a pretty ugly day for some of the more speculative corners of the stock market.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.